Dendrite Clinical Systems is delighted to report that our Managing Director, Dr Peter Walton, has published a chapter discussing the value of clinical registries in new publication on Laparoscopic Sleeve Gastrectomy (LSG). In his Chapter, Dr Peter Walton outlines value of national bariatric registries and their capability to deliver evidence on a global basis, as well as providing some practical perspectives on best practice when setting out to start a national registry and how to keep a good registry going.
Dendrite Clinical Systems and the Institute for Health Research (IGES) in Berlin, Germany, have initiated the Outpatient Treatment of COVID-19 Infections (ABC-19) study, to record data on the treatment of COVID-19 patients and discover more about the outpatient course of the disease, the individual risk factors of patients that contribute to severe COVID-19 courses and the procedures of general practitioners (GPs).
Researchers at the University College London and University College London Hospitals NHS Foundation Trust), London, UK, have reported that the vast majority of participants with new onset loss of smell were positive for COVID19, and this acute loss of sense of smell needs to be considered globally as a criterion for self-isolation, testing and contact tracing in order to contain the spread of COVID-19.
Dendrite Clinical Systems’ innovative “Intellect Web” software has been chosen by an international group of 17 leading diabetes experts from the multidisciplinary Diabetes Surgery Summit (DSS), as the platform on which the CoviDiab project will establish a Global Registry to collect new cases of diabetes in patients with COVID-19.
Dendrite and BSACI launch BRIT immunotherapy registry
Dendrite Clinical Systems and the British Society for Allergy & Clinical Immunology (BSACI) have launched the British Registry for Immunotherapy (BRIT), a web-based patient registry that records immunotherapy treatment of patients under the care of BSACI consultants practicing in the UK.
“We are delighted to launch the first national immunotherapy registry in the UK,” said Dr peter Walton, managing Director of Dendrite Clinical Systems. “By recording each and every serious adverse event during immunotherapy treatment, the BSACI we will be able to monitor the efficacy of immunotherapy enabling the BSACI to guide commissioning of services and guideline development.”
BRIT is a secure web-based registry that can record the use of Allergen Immunotherapy (AIT) by both subcutaneous and sublingual immunotherapy routes (also known as SCIT and SLIT). By venom immunotherapy (VIT) and the use of the monoclonal antibody Omalizumab (OMA) for Chronic Spontaneous Urticaria (CSU) in patients under the care of BSACI registered consultants. It will help consultants keep track of their patients and monitor their response to treatment by using email PROM reported directly by participants. It will also monitor safety and access to treatment around the UK.
To better understand what the current practises are in the UK, an online registry was developed by Dendrite using their “Intellect Web” software. This allows consultants to enter patient data online, using a range of modern html-5 compatible web browsers, without the need to install additional software or perform any complex system configurations.
The registry is open for all consultant BSACI members to register their practice(s) for both adult and paediatric patients. Additional healthcare professionals in the practice can register as users under the same practice in order to input data into the registry.
The registry is funded by unrestricted grants from three companies: AlK Abello, Allergy Therapeutics and Stallergenes.
